Drug profile

The FDA adverse-event record for Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution

71 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution. See the species affected, top reactions, and outcomes below.

71
adverse-event reports
18.3%
death-coded share
Cat
most-reported species
16
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
71
Total Reports
13
Deaths Reported
18.3%
Death Rate

Active Ingredients

Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution

Administration Routes

TopicalUnknownOralSubcutaneous

Species Affected

Cat 70
Dog 1

Most Affected Breeds

Domestic Shorthair 56
Domestic Mediumhair 7
Domestic Longhair 3
Cat (other) 2
Chihuahua 1
Persian 1
Maine Coon 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 16
Seizure NOS 9
Ataxia 9
Death 8
Lack of efficacy (ectoparasite) - flea 7
Application site hair loss 6
Tremor 6
Vomiting 6
Not eating 5
Hiding 5
Twitching 5
Death by euthanasia 5

Outcome Breakdown

Outcome Unknown
27 (38.0%)
Ongoing
16 (22.5%)
Recovered/Normal
15 (21.1%)
Died
8 (11.3%)
Euthanized
5 (7.0%)

Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution Adverse Event Insights

71 reports name Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution; 13 recorded a death outcome (18.3% of reported events, not a population-level mortality rate). Active ingredient: Eprinomectin 0.4% W/V / Esafoxolaner 1.2% W/V / Praziquantel 8.3% W/V Solution. Administration routes: Topical, Unknown, Oral, Subcutaneous.

By species: Cat (70 reports), Dog (1 reports). By breed: Domestic Shorthair (56), Domestic Mediumhair (7), Domestic Longhair (3).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (16), Seizure NOS (9), Ataxia (9), Death (8). Outcome, 71 coded reports: Outcome Unknown leads at 38.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.